Blood test to detect Alzheimer’s disease developed by scientists.
A group of neuroscientists, led by the University of Pittsburgh, US, have identified the biomarker, called “brain-derived tau”, or BD-tau. Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer’s disease-type neurodegeneration. Thus, brain-derived tau demonstrates the potential to complete the AT(N) scheme in blood and will be useful to evaluate Alzheimer’s disease-dependent neurodegenerative processes for clinical and research purposes-the study said which was published in the Brain journal.
“At present, diagnosing Alzheimer’s disease requires neuroimaging,” said senior author Thomas Karikari, University of Pittsburgh.
“Those tests are expensive and take a long time to schedule, and a lot of patients, even in the US, don’t have access to MRI and PET scanners. Accessibility is a major issue,” said Karikari.
“A blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trial and disease monitoring,” said Prof Thomas Karikari from the University of Pittsburgh.